Gene Doping

Pokrywka A, Kaliszewski P, Majorczyk E, Zembron-Lacny A. Genes in Sportand Doping. Biol Sport. 2013; 30, 155–61.

WADA. The 2018 prohibited list. (https://www.wadaama.org/sites/default/files/prohibited_ list_2018_en.pdf)

Beiter T, Velders M. Pimp my genes Gendoping zwischen Fakt und Fiktionen. Deutsche Zeitschrift für Sportmedizin. 2012; 63, 121-131.

Tatum EL. Molecular biology, nucleic acids, and the future of medicine. Perspectives in Biology and Medicine. 1966;10(1), 19–32.

Wirth T, Parker N, Ylä-Herttuala S. History of gene therapy. Gene. 2013; 525(2), 162–169.

Bouchard C, Hoffman EP (eds): Genetic and molecular aspects of sport performance. Volume XVIII of the Encyclopaedia of Sports Medicine an IOC Medical Commission Publication. Wiley-Blackwell 2011.

Ulucan K, Göle S. ACE I/D Polymorphism Determination in Turkish Elite Wind- surfers. Sports Science Review. 2014; XXIII(1-2), 79- 84.

Biyik B, Kapici S, Sercan C, Kulaksiz H, Yuksel İ, Ulucan K. Angiontensin Converting Enzyme Insertion/ Deletion Polymorphism Profile Of Turkish Professional Hip-Hop And Latin Dancers. Pamukkale Journal of Sport Sciences, 2018; 9(3), 49-54.

McCole SD, Shuldiner AR, Brown MD, et al. Beta2- and beta3- adrenergic receptor polymorphisms and exercise hemodynamics in postmenopausal women. Journal of Applied Physiology. 2004; 96, 526–530.

Eken BF, Sercan C, Kaya D, Ulucan K. Darbeye Bağlı Olmayan Yumuşak Doku Yaralanmalarında Moleküler Yaklaşım. Euroasian Research In Sport Science, 2018; 3(1), 15-25.

Aslan BT, Eken BF, Kaman T, Sercan C, Ulucan K. Collagen type I alpha 1 (COL1A1) rs1800012 polymorphism in cyclists. Pamukkale Journal of Sport Sciences. 2020; 11(2),1-4.

Yuksel Gozler İ, Can Kavas N, Polat T, Sercan Doğan C, Gozler T, Tacal Aslan B, Ulucan K. Analysis of HIF1A (rs11549465) polymorphism distributions in female volleyball players. Research in Sports Science. 2021; 11(1), 14-18.

Rahim M, Hobbs H, van der Merwe W, Posthumus M, Collins M, September AV. Investigation of angiogenesis genes with anterior cruciate ligament rupture risk in a South African population. J Sports Sci. 2018; 36(5), 551-557.

He Z, Hu Y, Feng, L, et al. Polymorphisms in the HBB gene relate to individual cardiorespiratory adaptation in response to endurance training. British Journal of Sports Medicine. 2006; 40, 998–1002.

Ulucan K, Bayyurt GM, Konuk M, Güney AI. Effect of alpha-actinin-3 gene on Turkish trained and untrained middle school children’s sprinting performance: a pilot study. Biological Rhythm Research. 2014; 45(4), 509- 514.

ulucan K, Biyik B, Kapici S, Sercan C, Yilmaz O, Catal T. Alpha-actinin-3 R577X Polymorphism Profile of Turkish Professional Hip-Hop and Latin Dancers. Ann Appl Sport Sci, 2016; 4(4), 01-06.

Eroğlu O, Zileli R, Nalbant MA, Ulucan K. Prevalence of alpha actinin-3 gene (ACTN3) R577X and angiotensin converting enzyme (ACE) insertion / deletion gene polymorphisms in national and amateur Turkish athletes. Cell Mol Biol (Noisy le Grand). 2018; 64 (5), 24-28.

Akcamli D, Sipahi S, Yuksel İ, Kavas NC, Polat T, Sercan C, Kapici S, Eken BF, Ulucan K. Futbolcularda Peroksizom Proliferatör–Aktive Reseptör Alfa rs4253778 Polimorfizm Dağılımının Belirlenmesi. Eurasian Research in Sport Science. 2018; 3(2), 75-79.

Wolfarth B. Genetics and ethics in elite sport. In: Bouchard C, Hoffmann EP, editors. Genetic and molecular aspects of sport performance. Oxford UK: Wiley-Blackwell; 2011: 151-158.

Unal M, Ozer Unal D. Gene doping in sports. Sports Medicine. 2004; 34, 357–362.

Tongers J, Roncalli JG, Losordo DW. Therapeutic angiogenesis for critical limb ischemia: Microvascular therapies coming of age. Circulation. 2008;18, 9–16.

Handschin C. The biology of PGC- 1alpha and its therapeutic potential. Trends in Pharmacological Sciences. 2009;30, 322–329.

Wells DJ. Gene doping: The hype and the reality. British Journal of Pharmacology. 2008; 154, 623–631.

Narkar VA, Downes M, Yu RT et al. AMPK and PPARdelta agonists are exercise mimetics. Cell, 134, 405–415.

Constantin D, Constantin-Teodosiu D, Layfield R, Tsintzas K, Bennett AJ Greenhaff PL. PPARdelta agonism induces a change in fuel metabolism and activation of an atrophy programme, but does not impair mitochondrial function in rat skeletal muscle. The Journal of Physiology. 2007; 583, 381–390.

Ulucan K, Topal ES, Aksulu BK, et al. Atletic Performance, Genetics and Gene Doping. İstanbul Kanuni Sultan Süleyman Tıp Dergisi. 2015; 7(2), 58–62.

Holt RIG, Sönksen PH. Growth hormone, IGF-I and insulin and their abuse in sport. Br J Pharmacol. 2008; 154, 542–556.

Tsuchida K. Targeting myostatin for therapies against muscle-wasting disorders. Current Opinion in Drug Discovery & Development. 2008; 11, 487–494.

Lee SJ. Quadrupling Muscle Mass in Mice by Targeting TGF-ß Signaling Pathways. PLOS ONE. 2007; 2(8): e789.

. Baoutina A, Alexander IE, Rasko JEJ, Emlie KR. Developing strategies for detection of gene doping. J Gene Med. 2008; 10, 3-20.

Dykxhoorn DM, Palliser D, Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Ther, 2006; 13, 41- 52.

Beiter T, Zimmermann M, Fragasso A, Hudemann J, Niess AM, Bitzer M, Lauer UM, Simon P. Direct and long-term detection of gene doping in conventional blood samples. Gene Ther. 2011; 18, 225- 231.